Today's glucose monitors push a needle-based filament 5 to 10mm under your skin. They track one thing: blood sugar. They cost a fortune. And only 1% of the nearly 600 million people living with diabetes worldwide actually use one.
@Savahealth just changed the equation.
Two
@imperialcollege bioengineers, Renato Circi (
@RENCIRCI) and Rafaël Michali, built a microsensor that's 10x shorter than conventional filaments. It's painless. It's cheaper to manufacture. And in a 46-person clinical trial across
@UniofOxford and
@Cambridge_Uni sites, it matched a leading commercial glucose monitor in accuracy over 10 days, with less than 1% difference.
That alone is a big deal. But here's what makes it bigger.
The same sensor platform is designed to read multiple molecules from just beneath your skin, not only glucose, but also lactate, ketones, cortisol, histamine, sodium, urea, and alcohol. Continuously. In real time. No blood draws. No lab visits.
Think about what that means in practice. Stress tracked through cortisol, not a questionnaire. Recovery and fitness measured by lactate, not guesswork. Metabolic health monitored through ketones while you sleep. Allergic responses detected by histamine before you even feel symptoms. All from one small, wearable patch.
This isn't a better glucose monitor. It's a molecular health platform. The kind of technology that turns "go see your doctor when something feels wrong" into "your body is telling you what's happening, right now, all the time."
$32M raised. Backed by
@balderton. Pivotal clinical study this year. Commercial launch targeted for 2027.
Congrats to the
@Savahealth team and
@jameswise for the coverage.
A big dose of Anglo-optimism:
UK-based
@Savahealth just announced world-first clinical evidence for effective continuous glucose monitoring via their proprietary microsensor technology.
Head-to-head with a leading CGM, across Oxford and Cambridge trial sites, Sava's microsensor performed at gold standard — with sensors 10x shorter than conventional filaments.
I road-tested one recently. It's smaller, painless, and does can do far more than track blood-glucose levels. Think Whoop meets medical-grade biosensing — sleep, movement, body temperature, blood glucose, and soon other molecules, all from one device.
This matters for the almost 1 billion people with Type 1 and 2 diabetes today, making CGMs cheaper and painless. But Sava is setting out to serve us all. It's what the shift from reactive to preventative healthcare actually looks like.
Britain building at the frontier of global biosensing - congrats team
@Savahealth.